Citizens Jmp Weighs in on Teleflex’s Q1 Earnings (NYSE:TFX)

Posted by Brian Himes on May 12th, 2026

Teleflex Incorporated (NYSE:TFX – Free Report) – Equities research analysts at Citizens Jmp issued their Q1 2027 earnings per share estimates for shares of Teleflex in a report released on Wednesday, May 6th. Citizens Jmp analyst D. Turkaly anticipates that the medical technology company will post earnings per share of $2.03 for the quarter. The consensus estimate for Teleflex’s current full-year earnings is $6.75 per share. Citizens Jmp also issued estimates for Teleflex’s Q2 2027 earnings at $2.62 EPS, Q3 2027 earnings at $2.83 EPS, Q4 2027 earnings at $3.05 EPS and FY2027 earnings at $10.50 EPS.

Teleflex (NYSE:TFX – Get Free Report) last announced its earnings results on Thursday, May 7th. The medical technology company reported $1.39 EPS for the quarter, topping analysts’ consensus estimates of $1.21 by $0.18. Teleflex had a positive return on equity of 13.29% and a negative net margin of 35.88%.The company had revenue of $548.30 million for the quarter, compared to analysts’ expectations of $536.91 million. During the same period last year, the firm earned $1.44 EPS. Teleflex’s revenue for the quarter was up 32.3% compared to the same quarter last year. Teleflex has set its FY 2026 guidance at 6.250-6.550 EPS.

A number of other equities research analysts have also recently commented on the company. Raymond James Financial reissued an “outperform” rating and set a $150.00 price target on shares of Teleflex in a report on Friday. Weiss Ratings reissued a “sell (d)” rating on shares of Teleflex in a report on Friday, March 27th. Wells Fargo & Company raised their price target on Teleflex from $130.00 to $138.00 and gave the company an “equal weight” rating in a report on Friday. Zacks Research raised Teleflex from a “strong sell” rating to a “hold” rating in a report on Tuesday, April 28th. Finally, Needham & Company LLC raised their price target on Teleflex from $138.00 to $147.00 and gave the company a “buy” rating in a report on Thursday, February 26th. Three analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $144.00.

View Our Latest Analysis on TFX

Teleflex Price Performance

Shares of Teleflex stock opened at $129.92 on Tuesday. Teleflex has a one year low of $100.18 and a one year high of $139.67. The stock’s fifty day moving average is $120.08 and its 200 day moving average is $116.73. The stock has a market cap of $5.75 billion, a P/E ratio of -5.70, a P/E/G ratio of 0.96 and a beta of 0.82. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.03 and a current ratio of 2.55.

Teleflex Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, March 31st. Stockholders of record on Friday, March 6th were issued a $0.34 dividend. This represents a $1.36 annualized dividend and a dividend yield of 1.0%. The ex-dividend date of this dividend was Friday, March 6th. Teleflex’s payout ratio is -5.96%.

Institutional Investors Weigh In On Teleflex

Several large investors have recently made changes to their positions in TFX. Banque Cantonale Vaudoise increased its holdings in shares of Teleflex by 82.5% in the fourth quarter. Banque Cantonale Vaudoise now owns 250 shares of the medical technology company’s stock worth $31,000 after purchasing an additional 113 shares during the last quarter. Hantz Financial Services Inc. increased its holdings in shares of Teleflex by 248.8% in the third quarter. Hantz Financial Services Inc. now owns 279 shares of the medical technology company’s stock worth $34,000 after purchasing an additional 199 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Teleflex in the third quarter worth about $35,000. V Square Quantitative Management LLC bought a new stake in shares of Teleflex in the fourth quarter worth about $37,000. Finally, Quent Capital LLC bought a new stake in shares of Teleflex in the third quarter worth about $38,000. 95.62% of the stock is owned by institutional investors.

Teleflex News Roundup

Here are the key news stories impacting Teleflex this week:

Positive Sentiment: Needham & Company reiterated a Buy rating on Teleflex and set a $147 price target, while projecting FY2028 EPS of $12.18 and Q1 2028 EPS of $2.90, signaling confidence in longer-term earnings growth. Needham & Company Teleflex estimate report
Positive Sentiment: Citizens JMP also raised its earnings expectations, forecasting FY2027 EPS of $10.50 and quarterly EPS of $2.03, $2.62, $2.83, and $3.05 for 2027, which suggests analysts see meaningful profit expansion ahead. Citizens JMP Teleflex estimate report
Neutral Sentiment: Truist Financial reaffirmed a Hold rating but lifted its price target to $143 from $135, implying moderate upside without a strong bullish shift. Teleflex Hold rating reaffirmed at Truist Financial

Teleflex Company Profile

(Get Free Report)

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company’s offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.